ATLANTA — Investigational new drug TNX-102 SL may provide clinically meaningful effects on function, fatigue, and sleep quality in patients with fibromyalgia, according to research results presented ...
Treatment was well tolerated with minimal effects on weight or blood pressure and discontinuation rate of 19% vs. placebo of 20.8% Data support the potential of Tonmya as a well-tolerated, centrally ...
Following its FDA approval in the summer, Tonix Pharma's fibromyalgia therapy Tonmya has been launched onto the market in the US, becoming the first new drug for the painful condition in more than 16 ...
A pharmaceutical company is recalling one of its products after discovering that the pill bottle could be filled with the wrong medication. According to the Food and Drug Administration (FDA), Unichem ...
Tonix plans to initiate potential pivotal Phase 2 HORIZON study of TNX-102 SL in adults with major depressive disorder in mid-2026More than 21 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback